Ozempic Pills: Cost, Safety, and Trust Behind the Growing Demand

As buzz grows around a potential pill version of Ozempic, a new survey reveals just how much this change could impact public interest, usage, and trust in the medication. Levity surveyed 1,000 people across the U.S. and the U.K. to learn how the format of Ozempic affects their willingness to try it and what concerns they might have about the shift from injections to pills. The findings suggest that removing the needle could make Ozempic more accessible, but not without raising a few eyebrows along the way.

Key Takeaways

• 1 in 2 people in the U.S. and the U.K. say injections are a barrier to using Ozempic.
• Roughly 3 in 5 (62%) would consider taking Ozempic if it were available as a pill.
• More than 3 in 4 (76%) trust that a pill version of Ozempic would be as safe and effective as the injection form.
• Nearly 20% are willing to pay $100 or more out of pocket each month for Ozempic pills.

Interest in Ozempic Pills Is High, But Cost and Effectiveness Still Matter

• Over half of men (52%) see injections as a barrier to using Ozempic, compared to 46% of women. Those who agree, by generation:
  
  • Baby boomers: 53%
  • Gen Z: 53%
  • Millennials: 50%
  • Gen X: 47%

• Over 3 in 5 men (63%) and women (61%) say they would consider taking Ozempic if it were available as a pill. Those who would do so, by generation:
  
  • Gen X: 65%
  • Millennials: 62%
  • Gen Z: 60%
  • Baby boomers: 53%

• On average, Americans and Brits would be willing to pay $35 per month out of pocket for Ozempic pills.

• Nearly 1 in 4 Americans (24%) would pay $100 or more per month for Ozempic pills, compared to 15% of Britons.

• Nearly 4 in 5 men (79%) and about 3 in 4 women (73%) trust that a pill version of Ozempic would be as safe and effective as the injection. Trust by generation:
  
  • Baby boomers: 79% 
  • Gen X: 76%
  • Millennials: 76% 
  • Gen Z: 75% 

• Nearly half of men who currently use Ozempic (48%) say they would definitely switch to a pill version, compared to just 36% of women. Willingness to switch from injectable to pill Ozempic, by generation:
  
  • Millennials: 44% 
  • Gen X: 34%
  • Gen Z: 17%
  • Baby boomers: 6% 

Top Concerns About Ozempic Being Offered as a Pill:

• People taking it without a prescription: 57%
• Overuse or abuse: 55%
• Long-term health effects: 50%
• Children or teens gaining access: 45%
• Increased black market or resale activity: 36%
• Cosmetic vs. medical misuse: 33%
• Negative impact on body image culture: 32%
• Insurance or pricing issues: 27%
• Pressure to take it: 16%
• Pressure from doctors or peers: 11%

• Over half of Americans (53%) do not believe Ozempic would become too accessible if offered as a pill, compared to only 36% of Brits.

• 46% of women and 43% of men do not believe Ozempic would become too accessible if offered as a pill. Those who agree, by generation:
  
  • Gen X: 50%
  • Millennials: 44%
  • Gen Z: 38%
  • Baby boomers: 37%

Methodology

We surveyed 500 Americans and 500 Britons to explore how the format of Ozempic, specifically the transition from injection to pill, shapes perceptions, willingness to use, and concerns about accessibility. Among Americans, the average age was 41; 50% were male, and 50% were female. Generationally, 9% were baby boomers, 31% were Gen X, 44% were millennials, and 17% were Gen Z. Among Britons, the average age was 42; 50% were male, and 50% were female. Generationally, 7% were baby boomers, 39% were Gen X, 38% were millennials, and 17% were Gen Z. Due to rounding, percentages may not total 100.

About Levity

Levity helps people lose weight with clinically-backed, GLP-1-based programs, including prescriptions like Ozempic, Wegovy, and Mounjaro. If you're considering switching to a GLP-1 pill or injection, Levity's expert care team can help you find the right fit. Learn more about GLP-1 medications, Ozempic, and other treatment options today.

Fair Use Statement

This content may be shared for noncommercial purposes with proper attribution. Please link back to Levity when citing this data.